Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 1694250.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A bladder tumor cell line resistant to doxorubicin (MGH-U1R) has been established previously by culturing a human transitional cell carcinoma cell line (MGH-U1) in increasing concentrations of the drug. MGH-U1R is 40 times more resistant to doxorubicin than MGH-U1. In the present study, MGH-U1R was evaluated for its multi-drug resistance or pleiotropism by testing against other chemotherapeutic agents. MGH-U1R was found to be 188 times more resistant to vinblastine and 13 times more resistant to etoposide than MGH-U1, while remained sensitive to bleomycin. Taken together with earlier evidence that the resistance of MGH-U1R to doxorubicin can be reversed by a calcium-channel blocker verapamil, and the measured over-expression of the mdr1 gene in these cells, MGH-U1R has the characteristic multiple drug resistance properties similar to other established doxorubicin resistant carcinoma cell lines. MGH-U1R may be a useful model for the development of strategies in overcoming drug-resistance in the treatment of transitional cell carcinoma.
Medical subject headings
- Doxorubicin
- Tumor Cells, Cultured
- Urinary Bladder Neoplasms